Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Steve Yang: AstraZeneca in China Wants to Transform Pharma R&D Models

publication date: Feb 3, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Steve Yang, AstraZeneca’s high profile VP and Head of R&D for Asian and Emerging Markets, is setting an ambitious goal for the company’s China R&D operation: “We will try to innovate and transform how we do R&D,” said Yang in a McKinsey Quarterly interview. Because innovative pharma development is still new in China, “we are starting with a clean slate,” he added. “But that could be an opportunity,” given that established ways of doing drug R&D are not institutionalized, leaving China free to map its own path. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...